about
Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patientsThe expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia.High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosisIncreased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosisSpleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation.JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis.Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment.Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosisEpitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritisTCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis.From the lab to the bedside: the present of research, i.e. the future of neonatology.Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease.Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis.JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.Constitutive Store-Operated Ca(2+) Entry Leads to Enhanced Nitric Oxide Production and Proliferation in Infantile Hemangioma-Derived Endothelial Colony-Forming Cells.Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis.JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis.Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates.CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis.Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial.Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.VEGF-induced intracellular Ca2+ oscillations are down-regulated and do not stimulate angiogenesis in breast cancer-derived endothelial colony forming cells.The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells.Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms.Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia.Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis.Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia.Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T cells in primary myelofibrosis.Increase of circulating endothelial cells in patients with Hereditary Hemorrhagic Telangiectasia.Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis.Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality markerCirculating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2–Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid MetaplasiaIncreased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarctionHigh-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled studyDifferent subsets of circulating angiogenic cells do not predict bronchopulmonary dysplasia or other diseases of prematurity in preterm infantsHigh circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130
P50
Q28484028-8C329355-3969-4282-A415-41785190E226Q33374489-193145D7-5091-4483-90A5-5514A6D62E6BQ33393259-3652CF2B-CD3E-42BC-8B77-C6D2F96F3E34Q33431469-E0559060-E1C3-481E-9D6E-BB0930CAB0C1Q34247430-9EC0AF0C-FD77-4677-AA90-ABB45FC179F9Q34468004-A7210B01-5279-4863-844A-B93D53D51457Q34652224-DFC305C4-3DCE-4C6A-BED7-B82BCF10F0A4Q35113804-7B44BDC7-4525-46F6-9000-D5D878414F11Q36047069-0CCCC961-5C77-4062-B81F-3B72CDF9A774Q36577387-4DC9BA67-BD72-498D-AC1B-4666FEAF7EAEQ36862456-A78A91FE-9BB0-46B4-9742-8E8363C30D23Q37356882-6A0DC7F3-149C-4476-8D8F-C1322A1FCAD4Q37616990-8C67BC7D-D560-490E-9E79-5DF1EC603C2FQ37833209-2FB07B91-C44C-4629-B0F5-982B11A59616Q38722134-70045A97-9AC2-4C9B-87A4-BFD654C910ACQ39662298-B00A3ECC-3258-434D-AF16-D039E6786507Q40181513-88D852AE-050E-464F-8E88-A36407E48532Q40225737-FB8E7288-94EF-4B9A-90BC-C77AE4380FACQ40626780-46A17992-D614-4284-A03B-74E29E6193FDQ40854467-69763CB1-FC42-4151-B211-4AED193B1D88Q43065879-46F9CAA6-C4EF-4BA6-8545-125E02444395Q43688338-9F2C2163-F03C-4256-86F0-3C797F0FA9E3Q44339744-E912D9E5-11C2-43CC-8A93-5543779D6811Q44785279-8E29D81C-860C-4E88-B614-0BB519E8333BQ46891342-C297EA91-FBDF-4273-94A5-C73EEA5EA403Q47137711-E47ABC1A-CE40-4087-995E-16EB3ACC3AA8Q48187895-5A4F98F2-BED0-4D52-9679-A83E1D4FCA3AQ51048904-828008AB-8CCC-45CC-B526-C7B82B6AE493Q51052766-0446BB26-7EEE-470A-B7E6-AE8D767EEC9CQ51970090-2AA75A66-18E5-472D-861F-E3F84C68576BQ52594464-440DA05C-EA0F-48C5-A05B-0435FFBF09A3Q52854029-2A5ABAC6-E8D7-468B-8886-CDFA90634730Q54304957-B5BA0615-18BA-4711-AC86-E4F419BE7BD4Q54442285-73C8390B-02FF-463A-ACDD-D0218BDE9F5BQ57589460-D1E70667-41BD-43C9-B395-888601F29709Q57589493-ABB9D8CD-D132-4F67-9118-17F66A5707F1Q57589498-FEE08631-8372-4D19-AAB5-3D5F850C56C7Q57786229-98F2677D-79B1-4B2D-8C68-E3C91DF15CF8Q58337369-2B4A1B08-762C-43DB-91E2-D885282DF1E3Q58535349-26324612-D92A-48BF-8F1E-1BA0467024DA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Margherita Massa
@ast
Margherita Massa
@en
Margherita Massa
@es
Margherita Massa
@nl
type
label
Margherita Massa
@ast
Margherita Massa
@en
Margherita Massa
@es
Margherita Massa
@nl
prefLabel
Margherita Massa
@ast
Margherita Massa
@en
Margherita Massa
@es
Margherita Massa
@nl
P106
P1153
6506110389
P31
P496
0000-0001-8037-0439